TY - JOUR
T1 - Correction to
T2 - First-in-Human Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques: Rationale and Design of the DEBuT-LRP Study (Journal of Clinical Medicine, (2023), 12, 18, (5807), 10.3390/jcm12185807)
AU - van Veelen, Anna
AU - Küçük, I. Tarik
AU - Fuentes, Federico H.
AU - Kahsay, Yirga
AU - Garcia-Garcia, Hector M.
AU - Beijk, Marcel A.M.
AU - den Hartog, Alexander W.
AU - Grundeken, Maik J.
AU - Vis, M. Marije
AU - Henriques, José P.S.
AU - Claessen, Bimmer E.P.M.
N1 - Publisher Copyright: © 2024 by the authors.
PY - 2024/3
Y1 - 2024/3
N2 - In the original publication [1], there was a mistake in Section 2.8. Statistical Considerations, Paragraph 1. The corrected version of Section 2.8. Statistical Considerations, Paragraph 1 appears below: Continuous baseline demographic and clinical variables will be presented in terms of percentiles (e.g., median, 25th, and 75th percentile or mean with standard deviation), while categorical variables are summarized in terms of frequencies and percentages. All p-values will be two-sided and a p-value of <0.05 will be considered statistically significant. The primary endpoint will be core-lab adjudicated and analyzed on both the lesion-level and the patient-level using a paired samples test. Missing data will be excluded from the analysis. The secondary endpoints will be summarized in frequencies and percentages. In the original publication [1], there was a mistake in Table 3, as published. The corrected version of Table 3 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
AB - In the original publication [1], there was a mistake in Section 2.8. Statistical Considerations, Paragraph 1. The corrected version of Section 2.8. Statistical Considerations, Paragraph 1 appears below: Continuous baseline demographic and clinical variables will be presented in terms of percentiles (e.g., median, 25th, and 75th percentile or mean with standard deviation), while categorical variables are summarized in terms of frequencies and percentages. All p-values will be two-sided and a p-value of <0.05 will be considered statistically significant. The primary endpoint will be core-lab adjudicated and analyzed on both the lesion-level and the patient-level using a paired samples test. Missing data will be excluded from the analysis. The secondary endpoints will be summarized in frequencies and percentages. In the original publication [1], there was a mistake in Table 3, as published. The corrected version of Table 3 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
UR - http://www.scopus.com/inward/record.url?scp=85187652886&partnerID=8YFLogxK
U2 - 10.3390/jcm13051479
DO - 10.3390/jcm13051479
M3 - Comment/Letter to the editor
SN - 2077-0383
VL - 13
JO - Journal of clinical medicine
JF - Journal of clinical medicine
IS - 5
M1 - 1479
ER -